A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery

Drug Safety

Volumn 34, Issue 6, 2011, Pages 449-463

  Schulman, Sam ^a,b,d   Majeed, Ammar ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Department of Medicine   (Sweden)

^d HHS General Hospital   (Canada)

Author keywords

Dabigatran etexilate; Enoxaparin sodium; Low molecular weight heparins; Orthopaedic surgery; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CLINICAL TRIAL; COMPRESSION GARMENT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; DYSPNEA; ETHNICITY; FEVER; HEALTH ECONOMICS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIP ARTHROPLASTY; HUMAN; HYPOKALEMIA; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; KNEE ARTHROPLASTY; LUNG EMBOLISM; NAUSEA; NONHUMAN; ORTHOPEDIC SURGERY; PERIPHERAL EDEMA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS FOOT PUMP; VENOUS THROMBOEMBOLISM; VOMITING; WOUND FLUID;

ANIMALS; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; ORTHOPEDIC PROCEDURES; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 79956206957     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11587290-000000000-00000     Document Type: Review

References (101)

1. Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009 Aug; 86 (2): 139-46
2. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabiga-tran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 Sep; 64 (3): 292-303 (Pubitemid 47283865)
3. EMEA. Public assessment report for Pradaxa 2008 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for- the-public/human/000829/WC500041060.pdf [Accessed 2011 Apr 1]
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 Sep 17; 361 (12): 1139-51
5. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous throm-boembolism. N Engl J Med 2009 Dec 10; 361 (24): 2342-52
6. AAOS. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmo-nary embolism in patients undergoing total hip or knee arthroplasty. Adopted by the American Academy of Or-thopedic Surgeons Board of Directors May 2007 [online]. Available from URL: http://www.aaos.org/ research/guidelines/PE-guideline.pdf [Accessed 2010 May 1]
7. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008 Jun; 133 (6 Suppl.): 381S-453S (Pubitemid 351894916)
8. Haddad FS, Kerry RM, McEwen JA, et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: a possible source of variation in reported patient outcomes. J Arthroplasty 2001 Jan; 16 (1): 37-46 (Pubitemid 32097228)
9. Freedman KB, Brookenthal KR, Fitzgerald Jr RH, et al. A meta-analysis of thromboembolic prophylaxis follow-ing elective total hip arthroplasty. J Bone Joint Surg Am 2000 Jul; 82-A (7): 929-38 (Pubitemid 30451931)
10. Brookenthal KR, Freedman KB, Lotke PA, et al. A metaanalysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001 Apr; 16 (3): 293-300 (Pubitemid 32303847)
11. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 338S-400S (Pubitemid 39302602)
12. Kim YH, Oh SH, Kim JS. Incidence and natural history of deep-vein thrombosis after total hip arthroplasty: a pro-spective and randomised clinical study. J Bone Joint Surg Br 2003 Jul; 85 (5): 661-5
13. Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007 Jul; 5 (7): 1438-43 (Pubitemid 46965372)
14. Seagroatt V, Tan HS, Goldacre M, et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991 Dec 7; 303 (6815): 1431-5
15. Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007 Jul 23; 167 (14): 1471-5 (Pubitemid 47124177)
16. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006 Mar; 88 (3): 386-91
17. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353 (9159): 1167-73 (Pubitemid 29155221)
18. Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003 Jun 17; 107 (23 Suppl. 1): I9-16
19. Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia: an epide-miological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost 2005 Dec; 3 (12): 2664-70 (Pubitemid 41819793)
20. Leizorovicz A. Epidemiology of post-operative venous thromboembolism in Asian patients: results of the SMART venography study. Haematologica 2007 Sep; 92 (9): 1194-200 (Pubitemid 350144177)
21. Nicolaides AN, Kakkar VV, Field ES, et al. The origin of deep vein thrombosis: a venographic study. Br J Radiol 1971 Sep; 44 (525): 653-63
22. Kakkar VV, Howe CT, Flanc C, et al. Natural history of postoperative deep-vein thrombosis. Lancet 1969 Aug 2; 2 (7614): 230-2
23. Moser KM, Fedullo PF, LitteJohn JK, et al. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994 Jan 19; 271 (3): 223-5 (Pubitemid 24041261)
24. Nielsen HK, Husted SE, Krusell LR, et al. Silent pulmonary embolism in patients with deep venous thrombosis: incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med 1994 May; 235 (5): 457-61 (Pubitemid 24212811)
25. Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989 Mar; 95 (3): 498-502 (Pubitemid 19094432)
26. Dorfman GS, Cronan JJ, Tupper TB, et al. Occult pulmonary embolism: a common occurrence in deep venous thrombosis. AJR Am J Roentgenol 1987 Feb; 148 (2): 263-6 (Pubitemid 17007212)
27. Williams JW, Britt LG, Eades T, et al. Pulmonary embolism after amputation of the lower extremity. Surg Gy-necol Obstet 1975 Feb; 140 (2): 246-8
28. Cruickshank MK, Levine MN, Hirsh J, et al. An evaluation of impedance plethysmography and 125I-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost 1989 Nov 24; 62 (3): 830-4 (Pubitemid 20004987)
29. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clin-ical Trial Group. J Bone Joint Surg Am 2001 Mar; 83-A (3): 336-45 (Pubitemid 32221562)
30. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004 Jan 12; 164 (1): 17-26 (Pubitemid 38067385)
31. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004 May 27; 350 (22): 2257-64
32. Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2005 Sep; 87 (9): 2097-112 (Pubitemid 41279143)
33. Dahl OE, Caprini JA, Colwell Jr CW, et al. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost 2005 May; 93 (5): 860-6 (Pubitemid 40691542)
34. Warwick D. New concepts in orthopaedic thromboprophylaxis. J Bone Joint Surg Br 2004 Aug; 86 (6): 788-92 (Pubitemid 39173461)
35. National Institutes of Health. Prevention of venous thrombosis and pulmonary embolism. Natl Inst Health Consens Dev Conf Consens Statement 1986; 6 (2): 1-8
36. Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006 Nov; 452: 175-80 (Pubitemid 44690665)
37. Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 2005 Dec; 87 (12): 1675-80 (Pubitemid 43009737)
38. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembo-lism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002 Sep 9; 162 (16): 1833-40
39. Lieberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am 1997 Mar; 79 (3): 319-25 (Pubitemid 27136639)
40. Lieberman JR, Sung R, Dorey F, et al. Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty. J Arthroplasty 1997 Feb; 12 (2): 180-4 (Pubitemid 27108289)
41. Pellegrini Jr VD, Donaldson CT, Farber DC, et al. The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res 2005 Dec; 441: 56-62 (Pubitemid 44384203)
42. Pellegrini Jr VD, Donaldson CT, Farber DC, et al. The Mark Coventry Award: prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006 Nov; 452: 21-7 (Pubitemid 44690637)
43. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007 Feb; 45 (2): 335-41
44. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003 Sep; 90 (3): 446-55 (Pubitemid 37138770)
45. Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. J Bone Joint Surg Br 1997 Sep; 79 (5): 780-6 (Pubitemid 27434498)
46. Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998 Apr 27; 158 (8): 873-8 (Pubitemid 28183642)
47. Colwell Jr CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: eva-luation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999 Jul; 81 (7): 932-40 (Pubitemid 29355002)
48. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand 2000 Feb; 71 (1): 47-50 (Pubitemid 30150555)
49. Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000 Jun 6; 132 (11): 853-61 (Pubitemid 30346847)
50. Anderson DR, Wilson SJ, Blundell J, et al. Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after ar-throplasty. J Bone Joint Surg Am 2002 Nov; 84-A (11): 1992-7 (Pubitemid 35283364)
51. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perio-perative administration of subcutaneous heparin: over-view of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988 May 5; 318 (18): 1162-73
52. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: compar-ison of LMW heparin and placebo. Acta Orthop Scand 1991 Feb; 62 (1): 33-8
53. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery: a ran-domized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992 Apr 2; 67 (4): 417-23
54. Levine MN, Gent M, Hirsh J, et al. Ardeparin (lowmolecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism: a randomized trial in patients undergoing knee surgery. Arch Intern Med 1996; 156 (8): 851-6 (Pubitemid 26119812)
55. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip ar-throplasty: a systematic review. Ann Intern Med 2001 Nov 20; 135 (10): 858-69 (Pubitemid 33070682)
56. Cohen AT, Bailey CS, Alikhan R, et al. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 2001 May; 85 (5): 940-1 (Pubitemid 32421835)
57. Eikelboom JW, Quinlan DJ, Douketis JD. Extendedduration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358 (9275): 9-15 (Pubitemid 32709732)
58. Samama CM, Vray M, Barre J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162 (19): 2191-6 (Pubitemid 35231587)
59. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, da-bigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004 Sep; 2 (9): 1573-80 (Pubitemid 40186173)
60. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005 Jan; 3 (1): 103-11 (Pubitemid 41647122)
61. Ho SJ, Brighton TA. Ximelagatran: direct thrombin inhibitor. Vasc Health Risk Manag 2006; 2 (1): 49-58
62. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a random-ised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370 (9591): 949-56 (Pubitemid 47393577)
63. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 Nov; 5 (11): 2178-85 (Pubitemid 47617868)
64. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American en-oxaparin regimen for prevention of venous thromboem-bolism after knee arthroplasty surgery. J Arthroplasty 2009 Jan; 24 (1): 1-9
65. Huo M, Eriksson B, Dahl O, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial [abstract no. 0564]. Haematologica 2010; 95 (Suppl. 2): 233
66. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee ar-throplasty: a meta-analysis. Thromb Haemost 2009 Jan; 101 (1): 77-85
67. Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboem-bolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010 Sep; 126 (3): 175-82
68. EMEA. CHMP assessment report for Pradaxa. Procedure no. EMEA/H/C/829 2008 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/pra daxa/H-829-en6.pdf [Accessed 2010 May 1]
69. Hanf W, Duntze J, Hida H, et al. The implication of a direct antithrombine in the appearance of (serious) post-operative acute respiratory distress. Ann Fr Anesth Re-anim 2009 Oct; 28 (10): 885-8
70. EMEA. Pradaxa: summary of product characteristics, 2008 [online]. Available from URL: http://www.ema. europa.eu/humandocs/PDFs/EPAR/pradaxa/emea- com bined-h829en.pdf [Accessed 2010 May 1]
71. Zauderer B. Age-related changes in renal function. Crit Care Nurs Q 1996 Aug; 19 (2): 34-40 (Pubitemid 26243621)
72. Dahl OE, Kurth AA, Rosencher N, et al. Efficacy and safety profile of dabigatran etexilate compared with en-oxaparin in primary venous thromboembolism preven-tion after total knee or hip replacement surgery in patients over 75 years [poster ID 437]. In: American Society of Hematology, 2008 [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper2885.html [Accessed 2010 May 1]
73. Dahl OE, Kurth AA, Rosencher N, et al. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery [poster ID 981]. In: American Society of Hematology, 2008 [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper2917.html [Accessed 2010 May 1]
74. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor-interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 Mar 29; 103 (6): 1116-27
75. Kapoor A, Chuang W, Radhakrishnan N, et al. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a system-atic review. Pharmacoeconomics 2010 Jul 1; 28 (7): 521-38
76. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol Assess 2009 Sep; 13 Suppl. 2: 55-62
77. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous throm-boembolism after hip or knee replacement surgery in adults 2008 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12059/42032/42032.pdf [Accessed 2011 Jan 9]
78. National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital, 2010 [online]. Available from URL: http://guidance.nice.org.uk/CG92/Guidance/pdf/ English [Accessed 2011 Jan 11]
79. McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27 (10): 829-46
80. Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009 Jan; 31 (1): 194-212
81. Wilke T, Neumann K, Klapper U, et al. Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals. Orthopade 2008 May; 37 (5): 448-56
82. Turpie A, Bauer K, Eriksson B, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003Aug; 90 (2): 364-6 (Pubitemid 36992515)
83. Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 2001 Sep; 16 (6): 679-88 (Pubitemid 32803634)
84. Mismetti P, Laporte S, Zufferey P, et al. Prevention of venous thromboembolism in orthopedic surgery with vita-min K antagonists: a meta-analysis. J Thromb Haemost 2004 Jul; 2 (7): 1058-70 (Pubitemid 40186077)
85. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip ar-throplasty. N Engl J Med 2008 Jun 26; 358 (26): 2765-75 (Pubitemid 351930851)
86. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the pre-vention of venous thromboembolism after total hip ar-throplasty: a double-blind, randomised controlled trial. Lancet 2008 Jul 5; 372 (9632): 31-9
87. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26; 358 (26): 2776-86 (Pubitemid 351930852)
88. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 May 16; 373 (9676): 1673-80
89. Huisman MV, Quinlan DJ, Dahl OE, et al. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010 Nov 1; 3 (6): 652-60
90. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010 Mar 6; 375 (9717): 807-15
91. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009 Aug 6; 361 (6): 594-604
92. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replace-ment. N Engl J Med 2010 Dec 23; 363 (26): 2487-98
93. Struijk-Mulder MC, Ettema HB, Verheyen CC, et al. Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. J Thromb Haemost 2010 Apr; 8 (4): 678-83
94. Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement: the influence of preventive intermittent calf compression and of surgical technique. Br J Surg 1983 Jan; 70 (1): 17-9 (Pubitemid 13176020)
95. Samama CM, Clergue F, Barre J, et al. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Br J Anaesth 1997 Jun; 78 (6): 660-5 (Pubitemid 27268074)
96. Francis CW, Pellegrini Jr VD, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replace-ment. JAMA 1992 Jun 3; 267 (21): 2911-5
97. Silbersack Y, Taute BM, Hein W, et al. Prevention of deep-vein thrombosis after total hip and knee replacement: low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br 2004 Aug; 86 (6): 809-12 (Pubitemid 39173465)
98. McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compres-sion. BMJ 1980 Feb 23; 280 (6213): 514-7 (Pubitemid 10163960)
99. Hull R, Delmore TJ, Hirsh J, et al. Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 1979; 16 (1-2): 37-45 (Pubitemid 10189965)
100. Haas SB, Insall JN, Scuderi GR, et al. Pneumatic sequentialcompression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg Am 1990 Jan; 72 (1): 27-31 (Pubitemid 20076552)
101. Kaempffe FA, Lifeso RM, Meinking C. Intermittent pneumatic compression versus coumadin: prevention of deep vein thrombosis in lower-extremity total joint ar-throplasty. Clin Orthop Relat Res 1991 Aug; 269: 89-97